Keep it nice and quite for a while boys still building positions in this one. IMO that ann is hinting at revenues. The other part I like is the focus on sales and not R&D like many other Pharmas in development. A question to all what are the chances of a cap raising anytime soon?
secondary listing on nasdaq, page-8
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
